X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-08-05 | PTIX | Protagenic Therapeutics, Inc.New | Armen Garo H | EXEC. CHAIR, PRINCIPAL OFF | P - Purchase | $0.26 | +5,000 | 31,294 | +19% | +$1,294 | ||||||
| D | 2026-08-04 | ELVN | Enliven Therapeutics, Inc. | Derynck Mika K | Dir | S - Sale+OE | $60.21 | -158,795 | 0 | -100% | -$9,561,587 | |||||
| D | 2026-08-04 | CORT | Corcept Therapeutics Inc | Guyer William | Chief Development Officer | S - Sale+OE | $113.13 | -3,700 | 3,985 | -48% | -$418,562 | |||||
| D | 2026-08-04 | IMNM | Immunome Inc. | Horn Kinney | CHIEF BUSINESS OFFICER | S - Sale+OE | $25.09 | -90,616 | 0 | -100% | -$2,273,555 | |||||
| M | 2026-08-04 | ADAG | Adagene Inc. | Luo Peter | CEO | P - Purchase | $3.65 | +23,245 | 180,745 | +15% | +$84,764 | |||||
2026-08-04 | PTCT | Ptc Therapeutics, Inc. | Klein Matthew B. | CEO | S - Sale | $68.57 | -10,292 | 383,868 | -3% | -$705,722 | ||||||
2026-08-05 | COCP | Cocrystal Pharma, Inc. | Frost Phillip Md Et Al | Dir, 10% | P - Purchase | $0.98 | +10,000 | 2,020,651 | 0% | +$9,816 | ||||||
| D | 2026-08-06 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $517.05 | -8,300 | 45,172 | -16% | -$4,291,512 | |||||
| D | 2026-08-05 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $518.74 | -9,500 | 668,728 | -1% | -$4,927,985 | |||||
2026-08-04 | ACRV | Acrivon Therapeutics, Inc. | Levy Adam D. | CFO | S - Sale | $1.57 | -1,142 | 66,008 | -2% | -$1,793 | ||||||
2026-08-04 | AGIO | Agios Pharmaceuticals, Inc. | Gheuens Sarah | Chief Medical Officer | S - Sale | $30.48 | -30,000 | 54,645 | -35% | -$914,400 | ||||||
2026-08-05 | PFE | Pfizer Inc | Damico Jennifer B. | SVP, Controller | S - Sale | $25.40 | -3,278 | 28,611 | -10% | -$83,261 | ||||||
| M | 2026-08-04 | TLSA | Tiziana Life Sciences Ltd | Elrifi Ivor | CEO | P - Purchase | $0.99 | +321,423 | 4,793,684 | +7% | +$318,909 | |||||
2026-08-03 | ARQT | Arcutis Biotherapeutics, Inc. | Burnett Patrick | See Remarks | S - Sale | $26.12 | -955 | 119,289 | -1% | -$24,942 | ||||||
2026-08-03 | ARQT | Arcutis Biotherapeutics, Inc. | Matsuda Masaru | See Remarks | S - Sale | $26.12 | -1,230 | 126,171 | -1% | -$32,124 | ||||||
2026-08-03 | ARQT | Arcutis Biotherapeutics, Inc. | Watanabe Todd | See Remarks | S - Sale | $26.12 | -4,375 | 950,337 | 0% | -$114,261 | ||||||
| D | 2026-08-03 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | CFO | S - Sale+OE | $95.57 | -7,500 | 97,994 | -7% | -$716,771 | |||||
2026-08-03 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | CEO | S - Sale | $95.51 | -15,000 | 567,540 | -3% | -$1,432,705 | ||||||
| D | 2026-08-03 | SEPN | Septerna, Inc. | Long Daniel D. | SVP, Drug Discovery | S - Sale+OE | $34.47 | -3,334 | 96,412 | -3% | -$114,920 | |||||
| D | 2026-08-05 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | Chief Scientific Officer | S - Sale+OE | $25.00 | -4,356 | 117,227 | -4% | -$108,900 | |||||
2026-08-03 | ALMS | Alumis Inc. | Schroer John R. | CFO | S - Sale | $26.37 | -3,282 | 24,718 | -12% | -$86,546 | ||||||
2026-08-03 | ALMS | Alumis Inc. | Pangali Sanam | GC | S - Sale | $26.37 | -1,364 | 9,747 | -12% | -$35,969 | ||||||
2026-08-03 | ALMS | Alumis Inc. | Hardiman Roy C. | Chief Business, Strategy Ofcr | S - Sale | $26.37 | -2,692 | 214,163 | -1% | -$70,988 | ||||||
2026-08-03 | ALMS | Alumis Inc. | Goldstein David M | Chief Scientific Officer | S - Sale | $26.37 | -2,596 | 248,201 | -1% | -$68,457 | ||||||
2026-08-03 | ALMS | Alumis Inc. | Drappa Jorn | Chief Medical Officer | S - Sale | $26.37 | -2,447 | 56,892 | -4% | -$64,527 | ||||||
2026-08-03 | ALMS | Alumis Inc. | Bradley Mark Christopher | Chief Development Officer | S - Sale | $26.37 | -2,572 | 88,585 | -3% | -$67,824 | ||||||
| D | 2026-08-03 | CORT | Corcept Therapeutics Inc | Maduck Sean | See Remarks | S - Sale+OE | $114.70 | -20,305 | 119,472 | -15% | -$2,329,075 | |||||
2026-08-03 | CORT | Corcept Therapeutics Inc | Lyon Joseph Douglas | See Remarks | S - Sale | $114.16 | -1,540 | 5,495 | -22% | -$175,806 | ||||||
2026-08-03 | ONC | Beone Medicines Ltd. | Rosenberg Aaron | CFO | S - Sale | $312.72 | -1,157 | 382,850 | 0% | -$361,811 | ||||||
2026-08-03 | CAMP | Camp4 Therapeutics Corp | Young Richard A | Dir | P - Purchase | $1.65 | +16,378 | 186,388 | +10% | +$27,024 | ||||||
2026-08-03 | CAMP | Camp4 Therapeutics Corp | Maricich Yuri | Chief Medical Officer | P - Purchase | $1.65 | +6,551 | 12,611 | +108% | +$10,809 | ||||||
2026-08-03 | CAMP | Camp4 Therapeutics Corp | Gold Kelly | CFO | P - Purchase | $1.65 | +6,551 | 74,428 | +10% | +$10,809 | ||||||
2026-08-03 | CAMP | Camp4 Therapeutics Corp | Mandel-Brehm Josh | CEO | P - Purchase | $1.65 | +6,551 | 284,968 | +2% | +$10,809 | ||||||
2026-08-04 | MBX | Mbx Biosciences, Inc. | Azoulay Salomon | Chief Medical Officer | S - Sale | $65.77 | -370 | 14,399 | -3% | -$24,335 | ||||||
2026-08-05 | INDV | Indivior Pharmaceuticals, Inc. | Anderson Woodrow D | Chief Accounting Officer | P - Purchase | $36.28 | +1,500 | 26,138 | +6% | +$54,420 | ||||||
2026-08-03 | VSTM | Verastem, Inc. | Paterson Dan | Pres, CEO | S - Sale | $5.81 | -1,302 | 589,940 | 0% | -$7,565 | ||||||
| D | 2026-08-04 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $517.09 | -9,500 | 668,728 | -1% | -$4,912,310 | |||||
2026-08-03 | JAZZ | Jazz Pharmaceuticals Plc | Cozadd Bruce C | Dir | S - Sale | $252.98 | -6,000 | 360,682 | -2% | -$1,517,880 | ||||||
2026-08-03 | TLSA | Tiziana Life Sciences Ltd | Elrifi Ivor | CEO | P - Purchase | $1.00 | +667,000 | 4,472,261 | +18% | +$667,000 | ||||||
2026-08-03 | MIRM | Mirum Pharmaceuticals, Inc. | Howe Jolanda | SVP, GLOBAL CONTROLLER | S - Sale | $105.29 | -1,840 | 1,274 | -59% | -$193,734 | ||||||
| D | 2026-08-03 | APMD | Apnimed, Inc. | Morningside Venture Investments Ltd | 10% | P - Purchase | $16.00 | +312,500 | 7,228,337 | +5% | +$5,000,000 | |||||
2026-08-03 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Chief Medical Officer | S - Sale | $29.04 | -7,176 | 20,422 | -26% | -$208,385 | ||||||
| D | 2026-08-03 | MBRX | Moleculin Biotech, Inc. | Foster Jonathan P. | CFO | P - Purchase | $0.00 | +293,333 | 305,673 | >999% | +$0 | |||||
| D | 2026-08-03 | MBRX | Moleculin Biotech, Inc. | Klemp Walter V | CEO, Pres | P - Purchase | $0.00 | +533,333 | 564,340 | >999% | +$0 | |||||
| D | 2026-08-03 | MBRX | Moleculin Biotech, Inc. | Picker Donald H | Chief Science Officer | P - Purchase | $0.00 | +173,333 | 174,086 | >999% | +$0 | |||||
2026-08-03 | COCP | Cocrystal Pharma, Inc. | Frost Phillip Md Et Al | Dir, 10% | P - Purchase | $0.94 | +75,000 | 2,010,651 | +4% | +$70,590 | ||||||
2026-08-04 | KRRO | Korro Bio, Inc. | Aiyar Ram | Pres, CEO | S - Sale | $10.84 | -5,802 | 73,659 | -7% | -$62,917 | ||||||
2026-08-05 | OGN | Organon & Co. | Drinane Juliana Papa | Head of Mfg, Supply | S - Sale | $13.57 | -14,761 | 18,475 | -44% | -$200,307 | ||||||
| D | 2026-08-03 | TEVA | Teva Pharmaceutical Industries Ltd | Jover Placid | See "Remarks" | S - Sale+OE | $34.88 | -12,827 | 6,774 | -65% | -$447,351 | |||||
2026-08-05 | PFE | Pfizer Inc | Blaylock Ronald E | Dir | P - Purchase | $25.46 | +39,231 | 71,688 | +121% | +$998,821 | ||||||
2026-08-05 | PFE | Pfizer Inc | Buckley Mortimer J | Dir | P - Purchase | $25.52 | +37,632 | 37,632 | New | +$960,369 | ||||||
| D | 2026-08-03 | TEVA | Teva Pharmaceutical Industries Ltd | Hughes Eric A | See "Remarks" | S - Sale+OE | $34.88 | -25,578 | 134,877 | -16% | -$892,051 | |||||
| D | 2026-08-03 | TNGX | Tango Therapeutics, Inc. | Crystal Adam | Pres, R, D | S - Sale+OE | $27.24 | -27,000 | 115,743 | -19% | -$735,517 | |||||
2026-08-04 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | Chief Scientific Officer | S - Sale | $24.36 | -4,111 | 117,227 | -3% | -$100,142 | ||||||
2026-08-04 | NRIX | Nurix Therapeutics, Inc. | Van Houte Hans | CFO | S - Sale | $24.36 | -4,761 | 40,166 | -11% | -$115,989 | ||||||
2026-08-03 | MPLT | Maplight Therapeutics, Inc. | Lillie James Woodruff | Chief Scientific Officer | S - Sale | $12.54 | -22,082 | 202,380 | -10% | -$276,908 | ||||||
2026-08-04 | GNLX | Genelux Corp | Yu Yong | Chief Scientific Officer | S - Sale | $2.94 | -653 | 268,371 | 0% | -$1,922 | ||||||
2026-08-04 | GNLX | Genelux Corp | Cappello Joseph | Chief Technical Officer | S - Sale | $2.95 | -653 | 328,737 | 0% | -$1,924 | ||||||
2026-08-04 | GNLX | Genelux Corp | Zindrick Thomas | Pres, CEO | S - Sale | $2.95 | -3,023 | 1,260,890 | 0% | -$8,905 | ||||||
| D | 2026-08-03 | LGND | Ligand Pharmaceuticals Inc | Reardon Andrew | CLO, Secretary | S - Sale+OE | $288.99 | -5,000 | 41,514 | -11% | -$1,444,951 | |||||
2026-08-03 | XERS | Xeris Biopharma Holdings, Inc. | McCulloch Kevin | See Remarks | S - Sale | $8.02 | -15,000 | 1,701,126 | -1% | -$120,240 | ||||||
2026-08-03 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | See Remarks | S - Sale | $8.01 | -16,666 | 1,144,462 | -1% | -$133,553 | ||||||
| D | 2026-08-03 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $516.06 | -9,500 | 668,728 | -1% | -$4,902,569 | |||||
2026-08-03 | IMNN | Imunon, Inc. | Eylward Susan | GC, Corp Sec | S - Sale | $1.57 | -2,541 | 2,896 | -47% | -$3,977 | ||||||
2026-08-03 | RARE | Ultragenyx Pharmaceutical Inc. | Parschauer Karah Herdman | EVP, GC | S - Sale | $24.92 | -1,900 | 92,562 | -2% | -$47,348 | ||||||
2026-08-03 | RARE | Ultragenyx Pharmaceutical Inc. | Horn Howard | CFO | S - Sale | $24.92 | -4,696 | 96,295 | -5% | -$117,024 | ||||||
| D | 2026-08-03 | ALKS | Alkermes Plc. | Snyderman Nancy Lynn Md | Dir | S - Sale+OE | $50.35 | -44,472 | 36,178 | -55% | -$2,239,076 | |||||
| D | 2026-08-03 | ALKS | Alkermes Plc. | Hopkinson Craig C. | EVP R, D, Chief Medical Office | S - Sale+OE | $48.58 | -9,000 | 69,389 | -11% | -$437,220 | |||||
2026-08-03 | ALKS | Alkermes Plc. | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | S - Sale | $48.58 | -2,034 | 225,456 | -1% | -$98,812 | ||||||
| D | 2026-08-03 | CTNM | Contineum Therapeutics, Inc. | Stengone Carmine N. | CEO, Pres | S - Sale+OE | $16.01 | -2,500 | 17,217 | -13% | -$40,029 | |||||
| D | 2026-08-03 | PGEN | Precigen, Inc. | Shah Rutul R | COO | S - Sale+OE | $6.50 | -33,772 | 497,751 | -6% | -$219,518 | |||||
| M | 2026-07-30 | NXTC | Nextcure, Inc. | Adar1 Capital Management, LLC | 10% | P - Purchase | $4.93 | +329,153 | 722,419 | +84% | +$1,624,121 | |||||
| D | 2026-08-03 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | GC | S - Sale+OE | $23.05 | -16,589 | 9,110 | -65% | -$382,358 | |||||
| M | 2026-07-30 | TRDA | Entrada Therapeutics, Inc. | 5Am Ventures V, L.P. | 10% | S - Sale | $6.93 | -116,474 | 3,939,905 | -3% | -$807,027 | |||||
2026-07-30 | PTIX | Protagenic Therapeutics, Inc.New | Armen Garo H | EXEC. CHAIR, PRINCIPAL Officer | P - Purchase | $0.18 | +26,291 | 26,291 | New | +$4,806 | ||||||
| M | 2026-07-30 | TRDA | Entrada Therapeutics, Inc. | Parmar Kush | Dir, 10% | S - Sale | $6.93 | -116,474 | 3,939,905 | -3% | -$807,027 | |||||
2026-07-30 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale | $323.69 | -1,044 | 325,312 | 0% | -$337,932 | ||||||
| D | 2026-07-31 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $518.96 | -9,500 | 668,728 | -1% | -$4,930,098 | |||||
| D | 2026-07-30 | CORT | Corcept Therapeutics Inc | Mokari Atabak | CFO | S - Sale+OE | $114.71 | -80,000 | 16,130 | -83% | -$9,177,109 | |||||
2026-07-30 | BBIO | Bridgebio Pharma, Inc. | Apuli Maricel | Chief Accounting Officer | S - Sale | $80.06 | -2,000 | 127,401 | -2% | -$160,120 | ||||||
2026-07-31 | PRQR | Proqr Therapeutics N.V. | De Boer Daniel Anton | CEO | P - Purchase | $1.77 | +200,000 | 500,000 | +67% | +$353,960 | ||||||
| D | 2026-08-03 | APMD | Apnimed, Inc. | Sekhri Paul J | Dir | P - Purchase | $16.00 | +12,500 | 12,500 | New | +$200,000 | |||||
2026-07-31 | ANIX | Anixa Biosciences Inc | Kumar Amit | CEO | P - Purchase | $3.47 | +5,000 | 657,000 | +1% | +$17,350 | ||||||
| D | 2026-07-30 | ACAD | Acadia Pharmaceuticals Inc | Thompson Elizabeth H.Z. | EVP, Head of Research, Dev | S - Sale+OE | $26.13 | -16,558 | 18,994 | -47% | -$432,663 | |||||
| M | 2026-07-30 | IONS | Ionis Pharmaceuticals Inc | Hayden Michael R | Dir | P - Purchase | $52.94 | +20,000 | 78,298 | +34% | +$1,058,700 | |||||
2026-07-29 | KNSA | Kiniksa Pharmaceuticals International, Plc | Cole G Bradley | Dir | S - Sale | $81.43 | -3,673 | 7,172 | -34% | -$299,092 | ||||||
2026-07-31 | PGEN | Precigen, Inc. | Thomasian Harry Jr. | CFO | S - Sale | $6.06 | -100,000 | 254,535 | -28% | -$606,000 | ||||||
| D | 2026-07-30 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $524.91 | -9,500 | 668,728 | -1% | -$4,986,594 | |||||
2026-07-29 | HCWB | Hcw Biologics Inc. | Wong Hing C | CEO, 10% | P - Purchase | $2.59 | +23,210 | 125,845 | +23% | +$59,998 | ||||||
2026-07-29 | HCWB | Hcw Biologics Inc. | Flowers Lee | SVP of Business Development | P - Purchase | $2.59 | +7,736 | 8,691 | +810% | +$19,998 | ||||||
2026-07-29 | HCWB | Hcw Biologics Inc. | Garrett Scott T | Dir | P - Purchase | $2.59 | +7,736 | 41,644 | +23% | +$19,998 | ||||||
2026-07-29 | PRTA | Prothena Corp Public Ltd Co | Kingston Anne Evans | Chief Strategy Officer | S - Sale | $8.47 | -7,662 | 55,782 | -12% | -$64,919 | ||||||
2026-07-29 | PRTA | Prothena Corp Public Ltd Co | Isaacs Michael John | GC, Company Sec. | S - Sale | $8.47 | -8,386 | 35,745 | -19% | -$71,055 | ||||||
| M | 2026-07-28 | MLPT | Maplight Therapeutics, Inc. | Catalyst4, Inc. | 10% | P - Purchase | $12.67 | +1,209,225 | 20,906,689 | +6% | +$15,314,794 | |||||
| D | 2026-07-30 | NRIX | Nurix Therapeutics, Inc. | Van Houte Hans | CFO | S - Sale+OE | $23.38 | -2,845 | 44,927 | -6% | -$66,524 | |||||
| D | 2026-07-30 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | GC | S - Sale+OE | $23.38 | -3,847 | 19,912 | -16% | -$89,954 | |||||
| D | 2026-07-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | Chief Scientific Officer | S - Sale+OE | $23.38 | -3,847 | 121,338 | -3% | -$89,954 | |||||
2026-07-28 | KPTI | Karyopharm Therapeutics Inc. | Poulton Stuart | EVP, Chief Development Officer | S - Sale | $7.10 | -189 | 94,632 | 0% | -$1,342 | ||||||
| D | 2026-07-30 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale+OE | $79.88 | -14,000 | 58,555 | -19% | -$1,118,320 | |||||
2026-07-29 | ANIP | Ani Pharmaceuticals Inc | Carey Stephen P. | SVP, CFO | S - Sale | $81.36 | -2,850 | 174,693 | -2% | -$231,876 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |